M. A. Petri

622 total citations
10 papers, 403 citations indexed

About

M. A. Petri is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, M. A. Petri has authored 10 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 5 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Pathology and Forensic Medicine. Recurrent topics in M. A. Petri's work include Systemic Lupus Erythematosus Research (10 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Lymphoma Diagnosis and Treatment (2 papers). M. A. Petri is often cited by papers focused on Systemic Lupus Erythematosus Research (10 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Lymphoma Diagnosis and Treatment (2 papers). M. A. Petri collaborates with scholars based in United States, United Kingdom and Italy. M. A. Petri's co-authors include Lisa Christopher‐Stine, Adnan N. Kiani, Laurence S. Magder, Wendy S. Post, Kathleen E. Sullivan, R H McLean, J A Winkelstein, B.J. Schmeckpeper, William Mullen and Ri‐bao Wei and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lupus and Arthritis & Rheumatism.

In The Last Decade

M. A. Petri

10 papers receiving 391 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. A. Petri United States 7 328 266 95 57 35 10 403
Gro Østli Eilertsen Norway 11 243 0.7× 247 0.9× 68 0.7× 44 0.8× 62 1.8× 22 367
L M Vilá Puerto Rico 5 439 1.3× 188 0.7× 80 0.8× 23 0.4× 27 0.8× 7 507
Vasileios Vazgiourakis Greece 10 200 0.6× 252 0.9× 52 0.5× 90 1.6× 57 1.6× 25 431
Alicia Eimon Argentina 9 186 0.6× 170 0.6× 70 0.7× 51 0.9× 44 1.3× 14 317
Francesca Miranda Italy 11 213 0.6× 140 0.5× 56 0.6× 63 1.1× 20 0.6× 19 323
Shereen Oon Australia 13 329 1.0× 253 1.0× 101 1.1× 37 0.6× 68 1.9× 33 469
Sara Croca United Kingdom 8 277 0.8× 208 0.8× 100 1.1× 23 0.4× 21 0.6× 13 343
S N Wong China 8 218 0.7× 191 0.7× 53 0.6× 31 0.5× 32 0.9× 10 303
Yunyun Fei China 9 203 0.6× 148 0.6× 30 0.3× 71 1.2× 44 1.3× 14 368
Francesca Saccon Italy 12 481 1.5× 308 1.2× 160 1.7× 38 0.7× 38 1.1× 23 575

Countries citing papers authored by M. A. Petri

Since Specialization
Citations

This map shows the geographic impact of M. A. Petri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. A. Petri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. A. Petri more than expected).

Fields of papers citing papers by M. A. Petri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. A. Petri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. A. Petri. The network helps show where M. A. Petri may publish in the future.

Co-authorship network of co-authors of M. A. Petri

This figure shows the co-authorship network connecting the top 25 collaborators of M. A. Petri. A scholar is included among the top collaborators of M. A. Petri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. A. Petri. M. A. Petri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Morand, Eric F., R. Furie, Edward M Vital, et al.. (2022). POS0190 EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 81. 327–328. 6 indexed citations
2.
3.
Pejchinοvski, Martin, Justyna Siwy, William Mullen, et al.. (2017). Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus. Lupus. 27(1). 6–16. 26 indexed citations
4.
Petri, M. A., Adnan N. Kiani, Wendy S. Post, Lisa Christopher‐Stine, & Laurence S. Magder. (2010). Lupus Atherosclerosis Prevention Study (LAPS). Annals of the Rheumatic Diseases. 70(5). 760–765. 170 indexed citations
5.
Kim-Howard, Xana, Amit K. Maiti, Juan‐Manuel Anaya, et al.. (2009). ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Annals of the Rheumatic Diseases. 69(7). 1329–1332. 59 indexed citations
6.
Clarke, A., J.R. Penrod, Y. St. Pierre, et al.. (2000). Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group.. PubMed. 27(11). 2597–604. 46 indexed citations
7.
Petri, M. A., et al.. (1999). Frequency of the Fc gamma RIIIA-158F allele in African American patients with systemic lupus erythematosus.. PubMed. 26(7). 1486–9. 37 indexed citations
8.
Sullivan, Kathleen E., et al.. (1998). The polymorphic CYP17 allele is not found with increased frequency in systemic lupus erythematosus. Arthritis & Rheumatism. 41(5). 940–941. 1 indexed citations
9.
Sasso, Eric H., Lucy A. Suzuki, Arthur R. Thompson, & M. A. Petri. (1997). Hereditary resistance to activated protein C: An uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies. Arthritis & Rheumatism. 40(9). 1720–1721. 7 indexed citations
10.
Sullivan, Kathleen E., M. A. Petri, B.J. Schmeckpeper, R H McLean, & J A Winkelstein. (1994). Prevalence of a mutation causing C2 deficiency in systemic lupus erythematosus.. PubMed. 21(6). 1128–33. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gro Østli Eilertsen Breakdown of academic impact, for papers by L M Vilá Breakdown of academic impact, for papers by Vasileios Vazgiourakis Breakdown of academic impact, for papers by Alicia Eimon Breakdown of academic impact, for papers by Francesca Miranda Breakdown of academic impact, for papers by Shereen Oon Breakdown of academic impact, for papers by Sara Croca Breakdown of academic impact, for papers by S N Wong Breakdown of academic impact, for papers by Yunyun Fei Breakdown of academic impact, for papers by Francesca Saccon
Rankless by CCL
2026